Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients

被引：61
|
作者：
Suzuki, A
Otani, K
Mihara, K
Yasui, N
Kaneko, S
Inoue, Y
Hayashi, K
机构：
[1] YAMAGATA UNIV,SCH MED,DEPT NEUROPSYCHIAT,YAMAGATA 99023,JAPAN
[2] YOSHITOMI PHARMACEUT IND LTD,CTR PHARMACEUT TECHNOL,FUKUOKA 871,JAPAN
[3] GUNMA UNIV,SCH HLTH SCI,DEPT ALLIED MED SCI,MAEBASHI,GUMMA 371,JAPAN
来源：
PHARMACOGENETICS | 1997年 / 7卷 / 05期
关键词：
CYP2D6; genotype; haloperidol; reduced haloperidol; steady-state plasma concentration;
D O I：
10.1097/00008571-199710000-00013
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：415 / 418
页数：4
相关论文
共 50 条
  • [21] Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
    Roland Berecz
    Alfredo de la Rubia
    Pedro Dorado
    Pedro Fernández-Salguero
    Marja-Liisa Dahl
    Adrián LLerena
    European Journal of Clinical Pharmacology, 2003, 59 : 45 - 50
  • [22] Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
    Berecz, R
    de la Rubia, A
    Dorado, P
    Fernández-Salguero, P
    Dahl, ML
    Llerena, A
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (01) : 45 - 50
  • [23] HALOPERIDOL AND REDUCED-HALOPERIDOL CONCENTRATIONS IN PLASMA FROM CHRONIC-SCHIZOPHRENIC PATIENTS
    AYMARD, N
    LEYRIS, A
    TOFFIS, V
    VIALA, A
    EPINETTE, C
    DELTEIL, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (06) : 2301 - 2302
  • [24] Effects of the CYP2D6*10 Allele on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
    Suzuki, Takeshi
    Mihara, Kazuo
    Nakamura, Akifumi
    Nagai, Goyo
    Kagawa, Shoko
    Nemoto, Kenji
    Ohta, Ikuya
    Arakaki, Hajime
    Uno, Tsukasa
    Kondo, Tsuyoshi
    THERAPEUTIC DRUG MONITORING, 2011, 33 (01) : 21 - 24
  • [25] Effects of the CYP2D6☆10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole in Japanese patients with schizophrenia
    Suzuki, T.
    Mihara, K.
    Nagai, G.
    Nakamura, A.
    Nemoto, K.
    Kagawa, S.
    Uno, T.
    Kondo, T.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 207 - 207
  • [26] Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline
    Morita, S
    Shimoda, K
    Someya, T
    Yoshimura, Y
    Kamijima, K
    Kato, N
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (02) : 141 - 149
  • [27] Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers
    Özdemir, V
    Tyndale, RF
    Reed, K
    Herrmann, N
    Sellers, EM
    Kalow, W
    Naranjo, CA
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (05) : 472 - 475
  • [28] Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients
    Yasui, N
    Tybring, G
    Otani, K
    Mihara, K
    Suzuki, A
    Svensson, JO
    Kaneko, S
    PHARMACOGENETICS, 1997, 7 (05): : 369 - 374
  • [29] The impact of the CYP2D6 polymorphism on haloperidol pharmacoldnetics and on the outcome of haloperidol treatment
    Brockmöller, J
    Kirchheiner, J
    Schmider, J
    Walter, S
    Sachse, C
    Müller-Oerlinghausen, B
    Roots, I
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) : 438 - 452
  • [30] In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol
    Pan, L
    Belpaire, FM
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (08) : 599 - 604
12345